T Cell Redirection Drives Natural Immune Response Against Solid Tumors with Asher Nathan NeoTX (Empowered Patient Podcast)

Dr. Asher Nathan, CEO of NeoTX talks about the company’s work developing immunotherapies for a wide range of solid tumors using their proprietary Selective T Cell Redirection (STR) platform.  This technology enables therapies that bind a genetically engineered super antigen to the tumor surface which trigger a native, controlled immune response that can kill the cancer with potentially fewer side effects than currently available therapies.  Asher discusses the company’s lead STR molecule, NAP, which is being developed to treat advanced cancers.  NAP, which has potential as both a monotherapy and in combination with checkpoint inhibitors, is currently in a Phase 1B clinical trial in collaboration with AstraZeneca.